Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

NCT06107673 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

144

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Dalpiciclib
DRUG: Aromatase inhibitor
DRUG: Docetaxel injection
DRUG: Epirubicin Hydrochloride Injection
DRUG: Cyclophosphamide injection

Sponsor

Hebei Medical University Fourth Hospital